http://orcid.org/0000-0001-8596-8122
References
- Otsuka Pharmaceutical Co Ltd. Prescribing information for Rexulti (brexpiprazole) tablets. 2015, Rockville, MD, USA.
- Mondal S, Saha I, Das S, et al. Oral aripiprazole-induced severe hypoglycemia. Ther Drug Monit. 2012;34(3):245–248.
- Suzuki Y, Watanabe J, Fukui N, et al. Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients. BMJ. 2009;338:a1792–a1792.
- Fagerholm V, Haaparanta M, Scheinin M. α2-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol. 2011;108(6):365–370.
- Melkersson K, Khan A, Hilding A, et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol. 2001;11(5):327–332.
- Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018;26(1):92–94.
- Stassinos G, Klein-Schwartz W. Comparison of pediatric atypical antipsychotic exposures reported to U.S. poison centers. Clin Toxicol. 2017; 55(1):40–45.
- Ishigooka J, Iwashita S, Higashi K, et al. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to japanese patients with schizophrenia. J Clin Pharmacol. 2018;58(1):74–80.
- Tadori Y, Higashi K, Iwashita S, et al. Safety, tolerability, and pharmacokinetics of brexpiprazole following single oral dosing in healthy Japanese adult male volunteers: a randomized, double-blind, placebo-controlled study. Jpn J Penurpsychoparmacol. 2017;37:133–138.
- Cobaugh DJ, Erdman AR, Booze LL, et al. Atypical antipsychotic medication poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45(8):918–942.